Moderna, Inc. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
Moderna, Inc. (MRNA) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $3.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-07-31
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $3.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $2.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $3.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $5.00M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $3.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $2.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $5.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $7.00M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $11.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $22.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $33.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $85.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $114.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $147.00M 10-K · filed 2025-02-21 |
| 2023-09-30 | $254.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $289.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $289.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $223.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $176.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $21.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-24 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-26 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-30 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-07 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-26 |
| 2019-09-30 | $9.00M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $36.50M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $135.80M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $82.80M 10-K · filed 2020-02-27 |
| 2017-12-31 | $602.00M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |